No material corporate news briefings were recorded for Amgen Inc. in the 30 days preceding this report's generation date of 2026-08-04. Consecutive prior reports dated 2026-07-27, 2026-07-19, and 2026-07-11 similarly noted the absence of material corporate news events within their respective windows [Brief - 2026-07-27].
For the trailing twelve months ending 2026-03-31, Amgen reported revenue of $37.22 billion, representing year-over-year growth of 5.76%. Net income for the same period was $7.80 billion, reflecting a net margin of 20.96%. Gross margin stood at 48.58% and operating margin at 28.39%. The company carried $12.04 billion in cash against $59.32 billion in total debt. The trailing P/E ratio was 26.37, with market capitalisation recorded at approximately $204.48 billion. EPS grew 4.38% year-over-year [SEC 10-Q - AMGN - 2026-03-31].
Institutional ownership activity was notably mixed in the most recent reporting period. Bridgewater added 389% to its AMGN position, representing a substantial increase in exposure, while Millennium added 47% to its position [SEC 13F - Bridgewater - Q2 2026] [SEC 13F - Millennium - Q2 2026]. In contrast, AQR Capital reduced its position by 30% and Citadel reduced its position by 9.4% [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Citadel - Q2 2026]. No insider transaction data was available for inclusion in this report.
The prevailing macro environment shows the 10-year US Treasury yield at 4.75% and the 2-year at 4.28%, producing a normal yield curve spread of 47 basis points [FRED DGS10] [FRED DGS2]. These conditions form the broader rate context within which large-cap pharmaceutical equities such as AMGN are currently priced. The divergent institutional positioning changes described above were the primary trigger for this report's generation.